Skye Bioscience, Inc. Class Action Lawsuit - SKYE
Case Summary
Investors who suffered a loss and would like to learn more, click here to contact us.
The Skye Bioscience class action lawsuit seeks to represent purchasers or acquirers of Skye Bioscience, Inc. (NASDAQ: SKYE) securities between November 4, 2024 and October 3, 2025, inclusive (the “Class Period”). Captioned Stout v. Skye Bioscience, Inc., No. 25-cv-03177 (S.D. Cal.), the Skye Bioscience class action lawsuit charges Skye Bioscience and certain of Skye Bioscience’s top executives with violations of the Securities Exchange Act of 1934.
If you suffered substantial losses and wish to serve as lead plaintiff of the Skye Bioscience class action lawsuit, please provide your information in the form on this page. You can also contact attorney J.C. Sanchez or Jennifer N. Caringal of Robbins Geller by calling 800/449-4900 or via e-mail at info@rgrdlaw.com. Lead plaintiff motions for the Skye Bioscience class action lawsuit must be filed with the court no later than January 16, 2026.
CASE ALLEGATIONS: Skye Bioscience is a clinical stage biopharmaceutical company that focuses on developing molecules to treat obesity, overweight, and metabolic diseases. According to the complaint, in August 2024, Skye Bioscience initiated its “CBeyond” clinical trial, a twenty-six-week, randomized, double-blind, placebo-controlled Phase 2a proof-of-concept study designed to assess Skye Bioscience’s nimacimab product candidate as a treatment for obesity and overweight.
The Skye Bioscience class action lawsuit alleges that throughout the Class Period defendants made false and/or misleading statement and/or failed to disclose that: (i) nimacimab was less effective than defendants had led investors to believe; and (ii) accordingly, nimacimab’s clinical, regulatory, and commercial prospects were overstated.
The Skye Bioscience class action lawsuit alleges that on October 6, 2025, Skye Bioscience announced topline data from the CBeyond clinical trial, disclosing that the “the nimacimab monotherapy arm did not achieve the primary endpoint of weight loss compared to placebo” and that “preliminary pharmacokinetic analysis showed lower than expected drug exposure, potentially indicating the need for higher dosing as a monotherapy.” On this news, the price of Skye Bioscience stock fell 60%, according to the complaint.
THE LEAD PLAINTIFF PROCESS: The Private Securities Litigation Reform Act of 1995 permits any investor who purchased or acquired Skye Bioscience securities during the Class Period to seek appointment as lead plaintiff in the Skye Bioscience class action lawsuit. A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class. A lead plaintiff acts on behalf of all other class members in directing the Skye Bioscience investor class action lawsuit. The lead plaintiff can select a law firm of its choice to litigate the Skye Bioscience shareholder class action lawsuit. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the Skye Bioscience class action lawsuit.
ABOUT ROBBINS GELLER: Robbins Geller Rudman & Dowd LLP is one of the world’s leading law firms representing investors in securities fraud and shareholder litigation. Our Firm has been ranked #1 in the ISS Securities Class Action Services rankings for four out of the last five years for securing the most monetary relief for investors. In 2024, we recovered over $2.5 billion for investors in securities-related class action cases – more than the next five law firms combined, according to ISS. With 200 lawyers in 10 offices, Robbins Geller is one of the largest plaintiffs’ firms in the world, and the Firm’s attorneys have obtained many of the largest securities class action recoveries in history, including the largest ever – $7.2 billion – in In re Enron Corp. Sec. Litig.